A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Ramucirumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 29 Nov 2018 Status changed from not yet recruiting to recruiting.
- 03 Oct 2018 New trial record